ImmunoMet Therapeutics, Inc.   Report issue

For profit Phase 1
Founded: Houston TX United States (2015)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2017
NCT03272256
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

ImmunoMet Therapeutics, Inc.

Active Ingredients

Drugs in Phase 1 Trials (1)

Lixumistat (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lymphoma (Phase 1)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 1
  • # of Trial APIs: 1